Nanomedicine News

RSS

USPTO Issues Patent Allowance for Amphoteric Liposomal Formulations

Marina Biotech, Inc., a leading RNAi-based drug discovery and development company, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for patent application U.S. 11/745,003 broadly covering amphoteric liposomal formulations, including the Company's proprietary SMARTICLES® technology, for delivery of siRNAs and other compounds with therapeutic application.

31 Aug 2010

Nanotherapeutics Files Investigational New Drug Application for NanoDTPA Capsule

Nanotherapeutics, Inc., announced that it has filed an Investigational New Drug (IND) Application with the Food and Drug Administration (FDA) for NanoDTPA™ an orally administered capsule that is a less invasive treatment alternative to the FDA approved injectable Zn-DTPA (diethylenetriamine pentacetic acid).

From Nanotherapeutics Inc. 31 Aug 2010

Maven Updates Nanotechnology in Life Sciences Research Database

Maven Semantic announces updates to their Nanotechnology in life sciences research database.

30 Aug 2010

Drug-Loaded Magnetic Nanoparticles Treat Blood Clots

If a drug can be guided to the right place in the body, the treatment is more effective and there are fewer side-effects. Researchers at Lund University in Sweden have now developed magnetic nanoparticles that can be ...

26 Aug 2010

New Microneedles Can Deliver Quantum Dots into Skin

Researchers from North Carolina State University have developed extremely small microneedles that can be used to deliver medically-relevant nanoscale dyes called quantum dots into skin – an advance that opens the door to new techniques for diagnosing and treating a variety of medical conditions, including skin cancer.

26 Aug 2010

Researchers Develop Organic LEDs Using New Nanomaterial

Electronic products pollute our environment with a number of heavy metals before, during and after they're used.

26 Aug 2010

Cerulean Pharma’s Nanopharmaceuticals Hold Promise in Cancer Therapy

Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that results of a Phase 1 clinical study of CRLX101 (formerly IT-101), Cerulean’s lead clinical development candidate, and pre-clinical data on Cerulean’s development candidate, CRLX288, were presented at the American Chemical Society National Meeting & Exposition, ongoing in Boston, Massachusetts.

26 Aug 2010